ProKidney Corp. (PROK) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 662.64M USD. 52-week range 1.30 to 3.48 USD. Data as of 2026-10-09.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in ...